Titre : Récepteurs ionotropes du glutamate

Récepteurs ionotropes du glutamate : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteurs ionotropes du glutamate : Questions médicales les plus fréquentes", "headline": "Récepteurs ionotropes du glutamate : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteurs ionotropes du glutamate : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-03", "dateModified": "2025-04-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteurs ionotropes du glutamate" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteurs au glutamate", "url": "https://questionsmedicales.fr/mesh/D017470", "about": { "@type": "MedicalCondition", "name": "Récepteurs au glutamate", "code": { "@type": "MedicalCode", "code": "D017470", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.720.200.450" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Récepteur de l'AMPA", "alternateName": "Receptors, AMPA", "url": "https://questionsmedicales.fr/mesh/D018091", "about": { "@type": "MedicalCondition", "name": "Récepteur de l'AMPA", "code": { "@type": "MedicalCode", "code": "D018091", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.720.200.450.400.100" } } }, { "@type": "MedicalWebPage", "name": "Récepteurs kaïnate", "alternateName": "Receptors, Kainic Acid", "url": "https://questionsmedicales.fr/mesh/D018092", "about": { "@type": "MedicalCondition", "name": "Récepteurs kaïnate", "code": { "@type": "MedicalCode", "code": "D018092", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.720.200.450.400.200" } } }, { "@type": "MedicalWebPage", "name": "Récepteurs du N-méthyl-D-aspartate", "alternateName": "Receptors, N-Methyl-D-Aspartate", "url": "https://questionsmedicales.fr/mesh/D016194", "about": { "@type": "MedicalCondition", "name": "Récepteurs du N-méthyl-D-aspartate", "code": { "@type": "MedicalCode", "code": "D016194", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.720.200.450.400.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Récepteurs ionotropes du glutamate", "alternateName": "Receptors, Ionotropic Glutamate", "code": { "@type": "MedicalCode", "code": "D058468", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Janesh Kumar", "url": "https://questionsmedicales.fr/author/Janesh%20Kumar", "affiliation": { "@type": "Organization", "name": "Laboratory of Membrane Protein Biology, National Centre for Cell Science, NCCS Complex, S. P. Pune University, Pune, Maharashtra, 411007, India. Electronic address: janesh@nccs.res.in." } }, { "@type": "Person", "name": "Ananth Prasad Burada", "url": "https://questionsmedicales.fr/author/Ananth%20Prasad%20Burada", "affiliation": { "@type": "Organization", "name": "Laboratory of Membrane Protein Biology, National Centre for Cell Science, NCCS Complex, S. P. Pune University, Pune, Maharashtra, 411007, India." } }, { "@type": "Person", "name": "Rajesh Vinnakota", "url": "https://questionsmedicales.fr/author/Rajesh%20Vinnakota", "affiliation": { "@type": "Organization", "name": "Laboratory of Membrane Protein Biology, National Centre for Cell Science, NCCS Complex, S. P. Pune University, Pune, Maharashtra, 411007, India." } }, { "@type": "Person", "name": "Darryl S Pickering", "url": "https://questionsmedicales.fr/author/Darryl%20S%20Pickering", "affiliation": { "@type": "Organization", "name": "Department of Drug Design and Pharmacology , University of Copenhagen , 2100 Copenhagen , Denmark." } }, { "@type": "Person", "name": "Margarita Anisimova", "url": "https://questionsmedicales.fr/author/Margarita%20Anisimova", "affiliation": { "@type": "Organization", "name": "Center for Neuroscience, University of California, Davis, Davis, CA 95618, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37399845", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jrsm.1652" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.", "datePublished": "2024-09-18", "url": "https://questionsmedicales.fr/article/39293856", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1183/16000617.0046-2024" } }, { "@type": "ScholarlyArticle", "name": "Topical anti-inflammatory treatments for eczema: network meta-analysis.", "datePublished": "2024-08-06", "url": "https://questionsmedicales.fr/article/39105474", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD015064.pub2" } }, { "@type": "ScholarlyArticle", "name": "Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.", "datePublished": "2023-08-31", "url": "https://questionsmedicales.fr/article/37650547", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD013730.pub2" } }, { "@type": "ScholarlyArticle", "name": "Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36691161", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-063884" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs aux neuromédiateurs", "item": "https://questionsmedicales.fr/mesh/D017981" }, { "@type": "ListItem", "position": 7, "name": "Récepteurs aux acides aminés", "item": "https://questionsmedicales.fr/mesh/D017459" }, { "@type": "ListItem", "position": 8, "name": "Récepteurs au glutamate", "item": "https://questionsmedicales.fr/mesh/D017470" }, { "@type": "ListItem", "position": 9, "name": "Récepteurs ionotropes du glutamate", "item": "https://questionsmedicales.fr/mesh/D058468" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteurs ionotropes du glutamate - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteurs ionotropes du glutamate", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteurs ionotropes du glutamate", "description": "Comment diagnostiquer une dysfonction des récepteurs glutamatergiques ?\nQuels examens sont utilisés pour évaluer l'activité des récepteurs ?\nLes tests génétiques sont-ils utiles pour ces récepteurs ?\nQuels symptômes peuvent indiquer un problème avec ces récepteurs ?\nComment les imageries cérébrales aident-elles au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteurs ionotropes du glutamate", "description": "Quels sont les symptômes d'une activation excessive des récepteurs ?\nComment une inhibition des récepteurs se manifeste-t-elle ?\nLes troubles moteurs sont-ils liés aux récepteurs glutamatergiques ?\nQuels effets cognitifs sont associés à ces récepteurs ?\nLes troubles du sommeil peuvent-ils être liés à ces récepteurs ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteurs ionotropes du glutamate", "description": "Peut-on prévenir les troubles liés aux récepteurs glutamatergiques ?\nL'exercice physique aide-t-il à la santé des récepteurs ?\nLes techniques de gestion du stress sont-elles bénéfiques ?\nLes habitudes de sommeil influencent-elles ces récepteurs ?\nLes compléments alimentaires sont-ils utiles pour la prévention ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteurs ionotropes du glutamate", "description": "Quels médicaments ciblent les récepteurs ionotropes du glutamate ?\nLa thérapie comportementale aide-t-elle avec ces récepteurs ?\nLes traitements nutritionnels influencent-ils ces récepteurs ?\nComment la stimulation cérébrale affecte-t-elle ces récepteurs ?\nLes thérapies géniques sont-elles une option pour ces récepteurs ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteurs ionotropes du glutamate", "description": "Quelles complications peuvent survenir avec une dysfonction des récepteurs ?\nLes troubles cognitifs peuvent-ils s'aggraver ?\nY a-t-il un risque accru de dépression ?\nLes troubles de l'humeur sont-ils fréquents ?\nDes problèmes de mémoire peuvent-ils être permanents ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteurs ionotropes du glutamate", "description": "Quels facteurs augmentent le risque de dysfonction des récepteurs ?\nL'usage de drogues influence-t-il ces récepteurs ?\nLe stress chronique est-il un facteur de risque ?\nLes maladies neurodégénératives augmentent-elles le risque ?\nL'âge est-il un facteur de risque pour ces récepteurs ?", "url": "https://questionsmedicales.fr/mesh/D058468?mesh_terms=Network+Meta-Analysis&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des récepteurs glutamatergiques ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests neurophysiologiques et des évaluations cliniques." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'activité des récepteurs ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme l'électrophysiologie et l'imagerie fonctionnelle sont utilisées." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour ces récepteurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des mutations affectant les récepteurs glutamatergiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec ces récepteurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles cognitifs, des convulsions ou des troubles de l'humeur peuvent survenir." } }, { "@type": "Question", "name": "Comment les imageries cérébrales aident-elles au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'observer des anomalies dans les zones cérébrales liées aux récepteurs." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une activation excessive des récepteurs ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Cela peut entraîner des convulsions, de l'anxiété et des troubles de la mémoire." } }, { "@type": "Question", "name": "Comment une inhibition des récepteurs se manifeste-t-elle ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer une dépression, une fatigue et des troubles de l'humeur." } }, { "@type": "Question", "name": "Les troubles moteurs sont-ils liés aux récepteurs glutamatergiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements peuvent entraîner des troubles moteurs et des spasmes." } }, { "@type": "Question", "name": "Quels effets cognitifs sont associés à ces récepteurs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes de concentration, de mémoire et de prise de décision peuvent survenir." } }, { "@type": "Question", "name": "Les troubles du sommeil peuvent-ils être liés à ces récepteurs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysrégulation des récepteurs peut affecter le cycle du sommeil." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés aux récepteurs glutamatergiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à la santé des récepteurs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la fonction cérébrale et les récepteurs." } }, { "@type": "Question", "name": "Les techniques de gestion du stress sont-elles bénéfiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent réduire l'impact négatif sur les récepteurs et la santé mentale." } }, { "@type": "Question", "name": "Les habitudes de sommeil influencent-elles ces récepteurs ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un bon sommeil est crucial pour la régulation des récepteurs et la santé cérébrale." } }, { "@type": "Question", "name": "Les compléments alimentaires sont-ils utiles pour la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains compléments peuvent soutenir la santé des récepteurs, mais avec prudence." } }, { "@type": "Question", "name": "Quels médicaments ciblent les récepteurs ionotropes du glutamate ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des antagonistes comme la kétamine et des modulateurs sont utilisés en clinique." } }, { "@type": "Question", "name": "La thérapie comportementale aide-t-elle avec ces récepteurs ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut améliorer les symptômes liés à la dysfonction des récepteurs." } }, { "@type": "Question", "name": "Les traitements nutritionnels influencent-ils ces récepteurs ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vitamines et acides gras peuvent moduler l'activité des récepteurs." } }, { "@type": "Question", "name": "Comment la stimulation cérébrale affecte-t-elle ces récepteurs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La stimulation cérébrale peut améliorer la fonction des récepteurs et réduire les symptômes." } }, { "@type": "Question", "name": "Les thérapies géniques sont-elles une option pour ces récepteurs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours pour utiliser la thérapie génique pour moduler ces récepteurs." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction des récepteurs ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques, des crises épileptiques et des troubles psychiatriques peuvent apparaître." } }, { "@type": "Question", "name": "Les troubles cognitifs peuvent-ils s'aggraver ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les troubles cognitifs peuvent s'aggraver avec le temps." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de dépression ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysfonction des récepteurs peut augmenter le risque de dépression sévère." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils fréquents ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent associés à des dysfonctionnements des récepteurs glutamatergiques." } }, { "@type": "Question", "name": "Des problèmes de mémoire peuvent-ils être permanents ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dommages prolongés aux récepteurs peuvent entraîner des problèmes de mémoire durables." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dysfonction des récepteurs ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux de troubles neurologiques et des traumatismes crâniens sont des facteurs de risque." } }, { "@type": "Question", "name": "L'usage de drogues influence-t-il ces récepteurs ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines drogues peuvent altérer la fonction des récepteurs glutamatergiques." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la régulation des récepteurs et la santé mentale." } }, { "@type": "Question", "name": "Les maladies neurodégénératives augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme Alzheimer peuvent affecter la fonction des récepteurs glutamatergiques." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour ces récepteurs ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut entraîner une dysfonction des récepteurs et des troubles cognitifs." } } ] } ] }

Sources (10000 au total)

Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.

With recent advancements in bronchoscopic procedures, data on the best modality to sample peripheral pulmonary lesions (PPLs) is lacking, especially comparing bronchoscopy with computed tomography-gui... We performed a meta-analysis, pairwise meta-analysis and network meta-analysis on studies reporting diagnostic yield and complications with the use of CT-TBNA, radial endobronchial ultrasound (rEBUS),... We included 363 studies. The overall pooled diagnostic yield was 78.1%, the highest with CT-TBNA (88.9%), followed by RAB (84.8%) and the least with rEBUS (72%). In the pairwise meta-analysis, only rE... Although CT-TBNA is the most effective approach to sample PPLs, RAB has a comparable diagnostic yield with a lesser complication rate. Further prospective studies are needed comparing CT-TBNA and RAB....

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti-inflammatory treatments are used to control eczema symptoms, but the... To compare and rank the efficacy and safety of topical anti-inflammatory treatments for people with eczema using a network meta-analysis.... We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies.... We included within-participant or between-participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoe... We used standard Cochrane methods. Primary outcomes were patient-reported eczema symptoms, clinician-reported eczema signs and investigator global assessment. Secondary outcomes were health-related qu... We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high-income countries in secondary care settings. Most studies included adults, wit... Potent TCS, JAK inhibitors and tacrolimus 0.1% were consistently ranked as amongst the most effective topical anti-inflammatory treatments for eczema and PDE-4 inhibitors as amongst the least effectiv...

Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.

Despite considerable improvement in outcomes for preterm infants, rates of bronchopulmonary dysplasia (BPD) remain high, affecting an estimated 33% of very low birthweight infants, with corresponding ... To determine whether differences in efficacy and safety exist between high-dose dexamethasone, moderate-dose dexamethasone, low-dose dexamethasone, hydrocortisone, and placebo in the prevention of BPD... We searched the Cochrane Library for all systematic reviews of systemic corticosteroids for the prevention of BPD and searched for completed and ongoing studies in the following databases in January 2... We included randomized controlled trials (RCTs) in preterm infants (< 37 weeks' gestation) at risk for BPD that evaluated systemic corticosteroids (high-dose [≥ 4 mg/kg cumulative dose] dexamethasone,... Our main information sources were the systematic reviews, with reference to the original manuscript only for data not included in these reviews. Teams of two paired review authors independently perfor... We included 59 studies, involving 6441 infants, in our analyses. Only six of the included studies provided direct comparisons between any of the treatment (dexamethasone or hydrocortisone) groups, for... Low-dose dexamethasone increased the risk for cerebral palsy (RR 1.92, 95% CI 1.12 to 3.28; moderate-certainty evidence) compared with control. Hydrocortisone may decrease the risk of major neurosenso... No effect was observed for the outcomes of major neurosensory disability or cerebral palsy. The evidence for the primary outcomes was of overall low certainty, with notable deductions for imprecision ... While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There...

Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.

Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and ac... We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous t... No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field.... CRD42021226034....

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability ... To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through networ... We searched CENTRAL, PubMed, Embase, two other databases and trials registers up to March 2022, together with reference checking and citation searching to identify additional studies.... We included participants 18 years of age or older with a diagnosis of MS or CIS, according to any accepted diagnostic criteria, who were included in randomized controlled trials (RCTs) that examined o... We used standard Cochrane methods for data extraction and pairwise meta-analyses. For NMAs, we used the netmeta suite of commands in R to fit random-effects NMAs assuming a common between-study varian... This NMA included 123 trials with 57,682 participants... We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no importan...

Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.

A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM),... We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk r... A total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin use... Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrate... PROSPERO [CRD42022361906]....

A network meta-analysis of surgical treatments of complete rectal prolapse.

Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and per... A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were... Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altem... Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates....

Efficacy and safety of COVID-19 vaccines: A network meta-analysis.

Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis t... Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of ... Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective i... We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 varian...